FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
19. April 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung...
Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
17. April 2024 02:00 ET
|
F. Hoffmann-La Roche Ltd
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%)...
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
15. April 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Columvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse large B-cell lymphoma Data from the...
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
11. April 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
The Elecsys® pTau217 plasma biomarker test is being developed as part of an ongoing partnership between Roche and Eli Lilly and CompanyOnce approved, the test will aid healthcare providers in...
Roche receives FDA approval for the first molecular test to screen for malaria in blood donors
26. März 2024 12:45 ET
|
F. Hoffmann-La Roche Ltd
The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malariaMalaria is a serious and potentially fatal parasitic infection most commonly transmitted by...
Roche Generalversammlung 2024
12. März 2024 08:30 ET
|
F. Hoffmann-La Roche Ltd
Alle Anträge des Verwaltungsrates genehmigtSeverin Schwan erneut als Präsident des Verwaltungsrates gewählt; alle weiteren zur Wahl stehenden Verwaltungsrätinnen und Verwaltungsräte bestätigt 37....
Assemblée générale 2024 de Roche
12. März 2024 08:30 ET
|
F. Hoffmann-La Roche Ltd
Adoption de toutes les propositions du Conseil d’administrationRéélection de Severin Schwan à la présidence du Conseil d’administration ; confirmation de tous les autres membres du Conseil...
Roche Annual General Meeting 2024
12. März 2024 08:30 ET
|
F. Hoffmann-La Roche Ltd
All proposals of the Board of Directors approvedSeverin Schwan re-elected as Chairman of the Board of Directors; all other Board members standing for election confirmed37th consecutive dividend...
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care
05. März 2024 07:30 ET
|
F. Hoffmann-La Roche Ltd
KARDIA-2 study met its primary endpoint, demonstrating clinically significant systolic blood pressure reductions in each treatment arm at month three Zilebesiran added to a standard of care...
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
25. Februar 2024 14:00 ET
|
F. Hoffmann-La Roche Ltd
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed...